2/11 Late treatment study
et al., J. Infection, doi:10.1016/j.jinf.2021.02.011 (Peer Reviewed)
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
Lora-Tamayo et al., 2/11/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors.
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7192, control 1361, odds ratio converted to relative risk, univariate.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.